Washington Ordered to Cover Hepatitis C Drugs During Lawsuit

  • Hepatitis C drugs cost as much as $94,500 before discounts
  • Washington verdict may set precedent for treatments nationally

Washington’s Medicaid program must pay for expensive hepatitis C treatments like Gilead Sciences Inc.’s Harvoni ahead of a trial to determine whether the state can exclude the medicine from being covered.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.